Cargando…

Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections

An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK–PD) analysis in patients with community-acquired respiratory tract infections (RTI). A population pharmacokinetic analysis of sitafloxacin was conducted using clinical data of five clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanigawara, Yusuke, Kaku, Mitsuo, Totsuka, Kyoichi, Tsuge, Hiroyuki, Saito, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824208/ https://www.ncbi.nlm.nih.gov/pubmed/23529500 http://dx.doi.org/10.1007/s10156-013-0580-2

Ejemplares similares

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
por: Tanigawara, Yusuke, et al.
Publicado: (2011)

1423. Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients With Pneumonia
por: Paiboonvong, Taniya, et al.
Publicado: (2018)

Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis
por: Manosuthi, Weerawat, et al.
Publicado: (2016)

Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid
por: Adjei-Sowah, Emmanuela, et al.
Publicado: (2021)

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
por: Chen, Yuancheng, et al.
Publicado: (2023)

A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia
por: Gao, Lei, et al.
Publicado: (2015)

The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species
por: Watanabe, Junko, et al.
Publicado: (2023)

Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data
por: Otani, Yuki, et al.
Publicado: (2021)

Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity
por: He, Siyuan, et al.
Publicado: (2022)

In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections
por: Davidson, Ross J
Publicado: (2019)

Comparative In Vitro Activity of Ciprofloxacin and Sitafloxacin Against Neisseria gonorrheae
por: Thamlikitkul, Visanu, et al.
Publicado: (2017)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Mixed community-acquired lower respiratory tract infections
por: Tarsia, Paolo, et al.
Publicado: (2007)

Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital
por: Hikone, Mayu, et al.
Publicado: (2015)

Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium
por: Durukan, Duygu, et al.
Publicado: (2020)

Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

1566. Population Pharmacokinetics of Voriconazole: Serum Albumin Status as a Novel Marker of Clearance and Dosage Optimization
por: Chantharit, Prawat, et al.
Publicado: (2019)

Cefditoren in upper and lower community-acquired respiratory tract infections
por: Soriano, Francisco, et al.
Publicado: (2011)

LABORATORY DIAGNOSIS OF COMMUNITY-ACQUIRED LOWER RESPIRATORY TRACT INFECTION
por: Saubolle, Michael A., et al.
Publicado: (2001)

Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria
por: Gai, Xiao-Yan, et al.
Publicado: (2019)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
por: Saito, Yoshimasa, et al.
Publicado: (2019)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy
por: Sue, Soichiro, et al.
Publicado: (2021)

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects
por: Sun, Lu‐Ning, et al.
Publicado: (2020)

2662. Efficacy of Sitafloxacin and Doxycycline Combination Therapy as a Salvage Treatment for Refractory Mycoplasma genitalium Infection
por: Ando, Naokatsu, et al.
Publicado: (2023)

Treatment of Community-Acquired Lower Respiratory Tract Infections during Pregnancy
por: Lim, Wei Shen, et al.
Publicado: (2012)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
por: Alghamdi, Wael A., et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial
por: Lojanapiwat, Bannakij, et al.
Publicado: (2019)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_734hi96aujl8lro8uj3gt6rb4a